Skip to main content
OpenTrials
Completed

NCT Number: NCT03784456

Impact of Increased Protein Density Diet to Muscle Mass and Strength Among Mid-aged and Older Adults

The subjects of this intervention program are mainly based on community-dwelling mid-aged and older adults. The investigator's program will provide meals containing different proportionated protein.As this project is a double blind test, only the investigators will know which subject corresponding to specific group of diets.

Besides, the investigators use the valued-based healthcare standard set as well as the Center for Epidemiological Studies-Depression, Charlson's comorbidity index Montreal Cognitive Assesment ,and Mini Nutritional Assessment as outcome measures and to use the randomized controlled trial design to validate if increased protein density diet could improve the vitality and health of mid-aged and old adults .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Muscle Loss Atrophy Fragility Muscle Weakness Muscular Atrophy Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Yang Ming University

Taipei, 112, Taiwan

About this study

With aging, functions of every organs become to decline. Muscle mass, is one of the decline. According to previous research, adults would lose 40% among from aged 20 to 70. If muscle mass decline combining with the decline of muscle strength is so called Sarcopenia.When muscle mass decline, infectious risk gets higher, and resilience after illness gets lower. In addition, activity and life quality are also responsible for falling, cognitive difficulty, disability and mortality among seniors. We hope to find out the etiologies of Sarcopenia through this program and develop prevention strategy and model to mollify the the negative effect of rapid aging society.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People who aged 40-75 years
  • Patients with following characteristics:
  • feeling loss in activity
  • detecting decline in self's walking speed.
  • feeling tired of doing everything.
  • having fell in last year.
  • People can accept undergoing MRI
  • People willing to follow the program and cooperate with us for following tracking.
  • People who are neither vegan nor vegetarian
  • People agree and be able to sign the informed consent.

Exclusion criteria

  • People cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets.
  • People with any disease affecting their limbs, including:
  • having fracture on limbs in the past 6 months
  • having severe arthritis in the past 6 months
  • any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
  • People with intermittent limp caused by peripheral artery diseases
  • People with weak control of mental disorder
  • People with weak control of Cardiopulmonary disease
  • People with weak control of Malignant tumor
  • People with weak control of kidney diseases (eGFR <60ml/min/1.73)
  • People with Visual impairment and Hearing disorder which cannot help to complete the program.
  • People who are unable to undertake MRI
  • People who have underwent hormone treatment and planned to undergo hormone treatment during program session.
  • Any other condition that PI recognized as not suitable

Treatment and study plan

25% protein

Dietary Supplement

Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.

15% protein

Dietary Supplement

Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.

Primary outcomes

  1. Changes from baseline muscle strength after 12 weeks

    Time frame: baseline,12 weeks

    measured by hand grip

  2. Changes form baseline QUALITY OF LIFE after 12 weeks

    Time frame: baseline, 12 weeks

    measured by the 36-Item Short Form Health Survey (SF-36), ranged 0-100, higher values represent a better condition

  3. Change from baseline Nutrition intake after 12 weeks

    Time frame: baseline, 12 weeks.

    measured by Mini-nutritional assessment questionnaire. ranged 0-30, higher values represent a better condition

  4. Change from baseline depression after 12 weeks

    Time frame: baseline,12 weeks

    measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition

  5. Change from baseline cognitive ability after 12 weeks

    Time frame: baseline, 12 weeks

    measured by Montreal Cognitive Assessment (MoCA) , ranged 0-30, higher values represent a better condition

  6. Change from baseline endurance after 12 weeks

    Time frame: baseline, 12 weeks

    measured by 6-minute walk distance

  7. Change from baseline walking speed after 12 weeks

    Time frame: baseline, 12 weeks

    measured by six-meter walking speed

  8. Change from baseline timed up and go test after 12 weeks

    Time frame: baseline, 12 weeks

    measured by timed up and go test (TUG) and six-meter walking speed

Secondary outcomes

  1. Change from baseline numbers of Complete blood count after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline numbers of Complete blood count after 12 weeks

  2. Change from baseline concentration of Albumin after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Albumin after 12 weeks

  3. Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks

  4. Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks

  5. Change from baseline concentration of blood urea nitrogen after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of blood urea nitrogen after 12 weeks

  6. Change from baseline concentration of Creatinin after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Creatinin after 12 weeks

  7. Change from baseline concentration of Fasting glucose after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Fasting glucose after 12 weeks

  8. Change from baseline concentration of Fasting insulin after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Fasting insulin after 12 weeks

  9. Change from baseline concentration of Total Cholesterol after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Total Cholesterol after 12 weeks

  10. Change from baseline concentration of Triglyceride after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of Triglyceride after 12 weeks

  11. Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks

  12. Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks

  13. Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks

  14. Change from baseline concentration of dehydroepiandrosterone after 12 weeks

    Time frame: baseline,12 weeks

    Change from baseline concentration of dehydroepiandrosterone after 12 weeks

  15. Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks

    Time frame: baseline, 12 weeks

    Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks

  16. Change from baseline concentration of Leptin after 12 weeks

    Time frame: baseline, 12 weeks

    Change from baseline concentration of Leptin after 12 weeks

  17. Change from baseline concentration of urine protein after 12 weeks

    Time frame: baseline, 12 weeks

    Change from baseline concentration of urine routine after 12 weeks

Sponsors and collaborators

Lead sponsor

National Yang Ming Chiao Tung University

Other

Collaborators

  • Laurel Corporation, Taiwan

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 24, 2018
Registry last updated
Feb 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.